Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer
暂无分享,去创建一个
I. Ellis | C. Caldas | E. Provenzano | A. Green | P. Pharoah | E. Rakha | G. Wishart | F. Blows | H. R. Ali | A. Green
[1] I. Ellis,et al. Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer , 2014, BMC Cancer.
[2] K. Byth,et al. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer , 2014, Journal of Clinical Pathology.
[3] Jack Cuzick,et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Balleine,et al. Ki67 and proliferation in breast cancer , 2013, Journal of Clinical Pathology.
[5] S. Cross,et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2 , 2012, British Journal of Cancer.
[6] C. Caldas,et al. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer , 2012, British Journal of Cancer.
[7] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[8] B. A. Carter,et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group , 2012 .
[9] Jack Cuzick,et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.
[10] J. Cuzick,et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Caldas,et al. A population-based validation of the prognostic model PREDICT for early breast cancer. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[12] Andrew R. Green,et al. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups , 2011, Breast Cancer Research and Treatment.
[13] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[14] Carlos Caldas,et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer , 2010, Breast Cancer Research.
[15] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[16] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[18] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[19] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[20] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[21] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[22] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[23] K. Sugimura,et al. The transcriptional inhibition of DNA repair protein Rad51 enhances radiosensitivity in prostate cancer cells , 2001 .
[24] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.